Portal de Periódicos da CAPES

How many biomarker measurements are needed to predict prognosis in Crohn's disease patients under infliximab?—A prospective study

2023; Wiley; Volume: 11; Issue: 6 Linguagem: Inglês

10.1002/ueg2.12420

2050-6414

Fernando Magro, María Manuela Estevinho, Gaia Catalano, Marta Patita, Bruno Arroja, Paula Lago, Isadora Rosa, Helena Tavares de Sousa, Paula Ministro, Irina Mocanu, Ana Vieira, Joana Castela, Joana Moleiro, Joana Roseira, Eugénia Cancela, Paula Sousa, Francisco Portela, L Correia, Paula Moreira, Mafalda Santiago, Sandra Fernandes Dias, Joana Afonso, Silvio Danese, Laurent Peyrin‐Biroulet, Cláudia Camila Dias,

Eosinophilic Esophagitis

Abstract Background Timely stratification of Crohn's disease (CD) is essential for patients' management. The use of noninvasive accurate biomarkers is key to monitor treatment and to pursue mucosal healing, the ultimate treatment endpoint in CD. Objective We aimed to evaluate the performance of readily available biomarkers and develop risk matrices to predict CD progression. Methods Data from 289 CD patients receiving infliximab (IFX) maintenance therapy for 2 years was collected; those patients were included in DIRECT, a prospective multicenter observational study. Disease progression was evaluated using two composite outcomes incorporating clinical and drug‐related factors, the first including IFX dose and/or frequency adjustments. Univariate and multivariable logistic regressions were used to calculate the odds ratios (OR) and to develop risk matrices. Results The isolated presence of anemia at least once during follow‐up was a significant predictor of disease progression (OR 2.436 and 3.396 [ p ≤ 0.001] for composite outcomes 1 and 2, respectively) regardless of confounding factors. Isolated highly elevated C‐reactive protein (CRP; >10.0 mg/L) and fecal calprotectin (FC; >500.0 μg/g) in at least one visit were also significant predictors, while milder elevations (3.1–10.0 mg/L and 250.1–500.0 μg/g) were only relevant when detected in at least two visits (consecutive or not). The combination of biomarkers in risk matrices had good ability to predict progression; patients simultaneously presenting anemia, highly elevated CRP and FC at least once had 42%–63% probability of achieving the composite outcomes. Conclusion The combined evaluation of hemoglobin, CRP, and FC in at least one time point and their incorporation into risk matrices seems to be the optimal strategy for CD management, as data from additional visits did not meaningfully influence the predictions and may delay decision‐making.